Switch to:
Also traded in: Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 2.91
VRTX's Cash to Debt is ranked lower than
77% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. VRTX: 2.91 )
Ranked among companies with meaningful Cash to Debt only.
VRTX' s Cash to Debt Range Over the Past 10 Years
Min: 1.15  Med: 2.20 Max: 26.61
Current: 2.91
1.15
26.61
Equity to Asset 0.45
VRTX's Equity to Asset is ranked lower than
80% of the 705 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. VRTX: 0.45 )
Ranked among companies with meaningful Equity to Asset only.
VRTX' s Equity to Asset Range Over the Past 10 Years
Min: 0.07  Med: 0.46 Max: 0.93
Current: 0.45
0.07
0.93
F-Score: 4
Z-Score: 5.39
M-Score: -0.13
WACC vs ROIC
15.23%
-52.35%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -23.94
VRTX's Operating margin (%) is ranked higher than
54% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -66.05 vs. VRTX: -23.94 )
Ranked among companies with meaningful Operating margin (%) only.
VRTX' s Operating margin (%) Range Over the Past 10 Years
Min: -602.63  Med: -112.58 Max: 8.07
Current: -23.94
-602.63
8.07
Net-margin (%) -30.91
VRTX's Net-margin (%) is ranked higher than
53% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -68.08 vs. VRTX: -30.91 )
Ranked among companies with meaningful Net-margin (%) only.
VRTX' s Net-margin (%) Range Over the Past 10 Years
Min: -630.27  Med: -111.44 Max: 2.1
Current: -30.91
-630.27
2.1
ROE (%) -41.17
VRTX's ROE (%) is ranked lower than
66% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -31.46 vs. VRTX: -41.17 )
Ranked among companies with meaningful ROE (%) only.
VRTX' s ROE (%) Range Over the Past 10 Years
Min: -180.27  Med: -58.14 Max: 4.58
Current: -41.17
-180.27
4.58
ROA (%) -16.69
VRTX's ROA (%) is ranked higher than
53% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -26.29 vs. VRTX: -16.69 )
Ranked among companies with meaningful ROA (%) only.
VRTX' s ROA (%) Range Over the Past 10 Years
Min: -58.14  Med: -29.94 Max: 1.51
Current: -16.69
-58.14
1.51
ROC (Joel Greenblatt) (%) -43.96
VRTX's ROC (Joel Greenblatt) (%) is ranked higher than
64% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. VRTX: -43.96 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
VRTX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1092.55  Med: -277.25 Max: 96.25
Current: -43.96
-1092.55
96.25
Revenue Growth (3Y)(%) -15.50
VRTX's Revenue Growth (3Y)(%) is ranked lower than
70% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. VRTX: -15.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
VRTX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -32.5  Med: 5.70 Max: 129.4
Current: -15.5
-32.5
129.4
» VRTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

VRTX Guru Trades in Q2 2015

Paul Tudor Jones 2,729 sh (New)
Kyle Bass 8,949 sh (New)
Andreas Halvorsen 1,805,186 sh (+1.98%)
Vanguard Health Care Fund 9,533,911 sh (unchged)
George Soros Sold Out
Jim Simons Sold Out
Lee Ainslie Sold Out
Steven Cohen Sold Out
Ken Fisher 4,378 sh (-0.18%)
Pioneer Investments 745,118 sh (-6.19%)
Louis Moore Bacon 80,000 sh (-17.95%)
» More
Q3 2015

VRTX Guru Trades in Q3 2015

Steven Cohen 15,000 sh (New)
Kyle Bass 100,000 sh (+1017.44%)
Ken Fisher 4,928 sh (+12.56%)
Louis Moore Bacon 50,000 sh (unchged)
Louis Moore Bacon Sold Out
Paul Tudor Jones Sold Out
Vanguard Health Care Fund 9,418,411 sh (-1.21%)
Pioneer Investments 670,780 sh (-9.98%)
Andreas Halvorsen 1,344,464 sh (-25.52%)
» More
Q4 2015

VRTX Guru Trades in Q4 2015

Paul Tudor Jones 6,286 sh (New)
Jim Simons 61,317 sh (New)
John Paulson 46,400 sh (New)
Joel Greenblatt 11,793 sh (New)
Pioneer Investments 767,325 sh (+14.39%)
Ken Fisher 5,543 sh (+12.48%)
Andreas Halvorsen 1,421,673 sh (+5.74%)
Vanguard Health Care Fund 9,827,411 sh (+4.34%)
Louis Moore Bacon 50,000 sh (unchged)
Spiros Segalas 657,494 sh (unchged)
Steven Cohen Sold Out
Kyle Bass Sold Out
» More
Q1 2016

VRTX Guru Trades in Q1 2016

Samuel Isaly 162,000 sh (New)
Ken Fisher 5,155 sh (-7.00%)
» More
» Details

Insider Trades

Latest Guru Trades with VRTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 17.36
VRTX's Forward P/E is ranked higher than
53% of the 87 Companies
in the Global Biotechnology industry.

( Industry Median: 17.92 vs. VRTX: 17.36 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 18.42
VRTX's P/B is ranked lower than
94% of the 843 Companies
in the Global Biotechnology industry.

( Industry Median: 3.49 vs. VRTX: 18.42 )
Ranked among companies with meaningful P/B only.
VRTX' s P/B Range Over the Past 10 Years
Min: 5.78  Med: 13.11 Max: 37.6
Current: 18.42
5.78
37.6
P/S 19.70
VRTX's P/S is ranked lower than
63% of the 674 Companies
in the Global Biotechnology industry.

( Industry Median: 11.42 vs. VRTX: 19.70 )
Ranked among companies with meaningful P/S only.
VRTX' s P/S Range Over the Past 10 Years
Min: 4.38  Med: 19.58 Max: 77.75
Current: 19.7
4.38
77.75
EV-to-EBIT -44.35
VRTX's EV-to-EBIT is ranked lower than
99.99% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 24.70 vs. VRTX: -44.35 )
Ranked among companies with meaningful EV-to-EBIT only.
VRTX' s EV-to-EBIT Range Over the Past 10 Years
Min: -64.9  Med: -12.30 Max: 208.5
Current: -44.35
-64.9
208.5
EV-to-EBITDA -51.16
VRTX's EV-to-EBITDA is ranked lower than
99.99% of the 275 Companies
in the Global Biotechnology industry.

( Industry Median: 20.64 vs. VRTX: -51.16 )
Ranked among companies with meaningful EV-to-EBITDA only.
VRTX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -74.9  Med: -13.40 Max: 114.7
Current: -51.16
-74.9
114.7
Current Ratio 2.78
VRTX's Current Ratio is ranked lower than
67% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. VRTX: 2.78 )
Ranked among companies with meaningful Current Ratio only.
VRTX' s Current Ratio Range Over the Past 10 Years
Min: 2.23  Med: 4.11 Max: 20.55
Current: 2.78
2.23
20.55
Quick Ratio 2.67
VRTX's Quick Ratio is ranked lower than
65% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. VRTX: 2.67 )
Ranked among companies with meaningful Quick Ratio only.
VRTX' s Quick Ratio Range Over the Past 10 Years
Min: 2.23  Med: 4.07 Max: 20.55
Current: 2.67
2.23
20.55
Days Inventory 110.18
VRTX's Days Inventory is ranked lower than
51% of the 440 Companies
in the Global Biotechnology industry.

( Industry Median: 120.79 vs. VRTX: 110.18 )
Ranked among companies with meaningful Days Inventory only.
VRTX' s Days Inventory Range Over the Past 10 Years
Min: 62.49  Med: 129.06 Max: 254.87
Current: 110.18
62.49
254.87
Days Sales Outstanding 51.39
VRTX's Days Sales Outstanding is ranked higher than
53% of the 603 Companies
in the Global Biotechnology industry.

( Industry Median: 66.24 vs. VRTX: 51.39 )
Ranked among companies with meaningful Days Sales Outstanding only.
VRTX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 25.75  Med: 47.58 Max: 106.15
Current: 51.39
25.75
106.15
Days Payable 167.97
VRTX's Days Payable is ranked higher than
84% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 63.23 vs. VRTX: 167.97 )
Ranked among companies with meaningful Days Payable only.
VRTX' s Days Payable Range Over the Past 10 Years
Min: 132.1  Med: 443.50 Max: 1204.41
Current: 167.97
132.1
1204.41

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 26.27
VRTX's Price/Tangible Book is ranked lower than
94% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. VRTX: 26.27 )
Ranked among companies with meaningful Price/Tangible Book only.
VRTX' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.01  Med: 11.38 Max: 75.31
Current: 26.27
3.01
75.31
Price/Median PS Value 1.01
VRTX's Price/Median PS Value is ranked lower than
54% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. VRTX: 1.01 )
Ranked among companies with meaningful Price/Median PS Value only.
VRTX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.26  Med: 0.95 Max: 3.65
Current: 1.01
0.26
3.65
Earnings Yield (Greenblatt) (%) -2.27
VRTX's Earnings Yield (Greenblatt) (%) is ranked higher than
65% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. VRTX: -2.27 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
VRTX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -2.27  Med: 2.80 Max: 5.4
Current: -2.27
-2.27
5.4

More Statistics

Revenue(Mil) $1032
EPS $ -2.30
Beta1.85
Short Percentage of Float2.04%
52-Week Range $75.90 - 143.45
Shares Outstanding(Mil)246.39

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 2,060 2,979 4,234
EPS($) 2.13 5.00 8.76
EPS without NRI($) 2.13 5.00 8.76

Business Description

Industry: Biotechnology » Biotechnology
Compare:XSWX:RO, OCSE:NOVO B, NAS:GILD, NAS:AMGN, NAS:CELG, NAS:BIIB » details
Traded in other countries:VX1.Germany, VRTX.Mexico, VRTX.Switzerland, 0QZU.UK,
Vertex Pharmaceuticals Inc was incorporated in 1989. The Company is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets. It is focused on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and early-stage development programs. The Company has marketed KALYDECO (ivacaftor) since it was approved in 2012 for the treatment of certain patients with CF and is seeking approval to market lumacaftor in combination with ivacaftor in order to increase the number of patients with CF who would be eligible for treatment with the Company's drugs. It is engaged in a number of other research and early-stage development programs, including programs in the areas of oncology and neurology. The Company's two products are INCIVE (telaprevir), which is approved for the treatment of patients with genotype 1 hepatitis C virus, or HCV, infection; and KALYDEC (ivacaftor), which is approved in the United States for the treatment of patients six years of age and older with cystic fibrosis, or CF, who genetic mutation in their cystic fibrosis transmembrane conductance regulator, or CFTR, gene, which is referred to as the G551D mutation. INCIVEK is approved in the United States and Canada for the treatment of adults with genotype 1 hepatitis C virus, or HCV, infection. As the Company markets and sells its approved products and advances its drug candidates through clinical development toward commercialization, it continues to build and maintain its supply chain and quality assurance resources. It faces competition based on the safety and efficacy of its products and drug candidates, the timing and scope of regulatory approvals, the availability and cost of supply, marketing and sales capabilities, reimbursement coverage, price, patent protection and other factors. Its registered trademarks include Vertex, KALYDECO and INCIVEK. The research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, safety monitoring, record keeping, promotion, advertising, distribution and marketing of its products and drug candidates are subject to extensive regulation by United States and foreign governmental authorities.
» More Articles for VRTX

Headlines

Articles On GuruFocus.com
Kyle Bass Sells Stakes in 11 Health Care Companies Mar 01 2016 
Lee Ainslie Adds 90 New Stocks to His Portfolio Within the First Quarter May 20 2015 
Analysts Confident That Vertex Pharmaceuticals' CF Drug Will Receive FDA Approval May 13 2015 
Fate Of Cystic Fibrosis Drug By Vertex Is Now Dependent On FDA Approval May 13 2015 
J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
William Blair’s Top BioPharmaceutical Stock Picks for Q1 2015 Dec 23 2014 
Weekly CFO Sells Highlight: Texas Instruments Inc, Royal Caribbean Cruises Ltd, Vertex Pharmaceutica Nov 09 2014 
Weekly CFO Sells Highllight: Facebook Inc, Vertex Pharmaceuticals Inc, Nike Inc. Oct 05 2014 
Vanguard Health Care Fund Buys Vertex Pharmaceuticals, Zoetis Inc, , Sells Cerner Corporation, AbbVi Aug 02 2013 
Weekly Guru Bargains Highlights: MBI, VRTX, GRPN, PBI, PC Dec 16 2012 

More From Other Websites
Vertex cut CEO pay by 23% last year amid executive-pay overhaul Apr 29 2016
A Typical Bad First Quarter For Biotech: Leerink Apr 29 2016
Vertex Pharmaceuticals, Inc. :VRTX-US: Earnings Analysis: Q1, 2016 By the Numbers Apr 29 2016
Vertex Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VRTX-US :... Apr 29 2016
Vertex aims at not only new patients, but on keeping those they have Apr 28 2016
Top Analyst Upgrades and Downgrades: Facebook, First Solar, Hess, Texas Instruments, US Steel,... Apr 28 2016
Short Sellers Dump Vertex, Load Up On Baxalta Apr 28 2016
Vertex Pharma downgraded by Goldman Apr 28 2016
Will Vertex (VRTX) Stock Decline on 1Q Earnings Miss? Apr 28 2016
Edited Transcript of VRTX earnings conference call or presentation 27-Apr-16 9:00pm GMT Apr 27 2016
[$$] Vertex Pharmaceuticals' Cystic Fibrosis Drug Disappoints Apr 27 2016
Vertex Forecasts Billion-Dollar Sales for Cystic Fibrosis Drug in '16 Apr 27 2016
Vertex Reports First Quarter 2016 Financial Results Apr 27 2016
VERTEX PHARMACEUTICALS INC / MA Files SEC form 8-K, Results of Operations and Financial Condition,... Apr 27 2016
Vertex reports 1Q loss Apr 27 2016
Vertex reports 1Q loss Apr 27 2016
4:05 pm Vertex Pharma misses by $0.19, misses on revs; guides Orkambi rev; raises kalydeco rev... Apr 27 2016
Vertex Reports First Quarter 2016 Financial Results Apr 27 2016
Charts Say Vertex Could Recover Apr 27 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK